TY - JOUR T1 - Biodistribution and Radiation Dosimetry of the Dopamine D<sub>2</sub> Ligand <sup>11</sup>C-Raclopride Determined from Human Whole-Body PET JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 313 LP - 319 VL - 47 IS - 2 AU - Mark Slifstein AU - Dah-Ren Hwang AU - Diana Martinez AU - Jesper Ekelund AU - Yiyun Huang AU - Elizabeth Hackett AU - Anissa Abi-Dargham AU - Marc Laruelle Y1 - 2006/02/01 UR - http://jnm.snmjournals.org/content/47/2/313.abstract N2 - Whole-body radiation dosimetry of 11C-raclopride was performed in healthy human volunteers. Methods: Subjects (n = 6) were scanned with PET. Subjects received single-bolus injections of 11C-raclopride (S-(−)-3,5-dichloro-N-[(1-ethyl-2-pyrrolidinyl)]methyl-2-hydroxy-6-methoxybenzamide) (533 ± 104 MBq) and were scanned for approximately 110 min with a 2-dimensional whole-body protocol. Regions of interest were placed over all visually identifiable organs and time–activity curves were generated. Residence times were computed as the area under the curve of the time–activity curves, normalized to injected activities and standard values of organ volumes. Absorbed doses were computed according to the MIRD schema with MIRDOSE3.1 software. Results: Organs with the highest radiation burden were gallbladder wall, small intestine, liver, and urinary bladder wall. Conclusion: On the basis of the estimated absorbed dose, the maximum allowable single study dose under U.S. federal regulations for studies performed under Radiation Drug Research Committee is 1.58 GBq (42.8 mCi). This is still considerably higher than the doses of 11C-raclopride commonly used in research PET (370−555 MBq). ER -